



COPY OF PAPERS
ORIGINALLY FILED

MSB-7267

RECEIVED

AUG 09 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/29C

In re Application of: Wang, et al.

Group No.: 1646

Serial Number: 09/605,577

Examiner: J Seharaseyon

Filed: 6/28/00

Title: STABILIZED INTERLEUKIN-2

Assistant Commissioner for Patents
Washington, D.C. 20231

Supplemental Response after Final Action

Sir:

Please consider the following supplemental comments to the Final Office Action (Paper No. 8) dated October 24, 2001:

In Paper No. 7, applicants argued that the rejections of Claims 1-6, 9 and 10 under 35 USC 103 were improper and that the Office had not met its burden under MPEP 2142.

In summary, applicants argued:

- 1) The target molecules in the Lee and Hora patents are very different molecules, and a skilled practitioner in the art **would not conclude** that the technology applicable to one (recombinant Factor VIII) would obviously apply to the other Interleukin-2 (IL-2). Because of the differences in functionality, size, and structural variety, it is **not** obvious that the stabilization technology applicable to one would serve the same purpose for use with the other.